MA H763

Establishes a special commission to investigate the feasibility of state-sponsored prescription drug manufacturing or distribution in Massachusetts, chaired by the Secretary of Health and Human Services

Commission includes 17 members representing state agencies, UMass, healthcare organizations, patient advocacy groups, and physicians with expertise in diabetes, substance use disorders, allergies, and asthma

Focuses on four key drugs: insulin, naloxone, albuterol inhalers, and epinephrine, assessing whether the state could manufacture or distribute them at reduced or no cost to low-income residents

Commission must evaluate partnership opportunities with public universities and existing manufacturers, study other states' initiatives, analyze regulatory obstacles, and explore interstate compacts with New England states

Final report with findings and policy recommendations due to the legislature by September 1, 2026